Influence of Histidine Administration on Ammonia and Amino Acid Metabolism: A Review

Milan Holeček

Department of Physiology, Charles University, Faculty of Medicine in Hradec Králové, Czech Republic

Support: Supported by the programme PROGRES Q40/02.

Correspondence:
Milan Holeček
Charles University
Faculty of Medicine in Hradec Králové
Šimkova 870
500 03 Hradec Králové
Czech Republic
Tel./Fax: +420-49-5210190
E-mail: holecek@lfhk.cuni.cz

Running title: Histidine, ammonia, and other amino acids

Abbreviations
ALA, alanine; AAA, aromatic amino acids; BCAA, branched-chain amino acids (valine, leucine, and isoleucine); FIGLU, formiminoglutamate; GLN, glutamine; GLU glutamic acid; HCD, histidine-containing dipeptides; HIS, histidine; HTK solution, histidine-tryptophan-ketoglutarate solution; MET, methionine; THF, tetrahydrofolate, α-KG, α-ketoglutarate
Summary

Histidine (HIS) is an essential amino acid investigated for therapy of various diseases, used for tissue protection in transplantation and cardiac surgery, and as a supplement to increase muscle performance. The data presented in the review show that HIS administration may increase ammonia and affect the level of several amino acids. The most common are increased levels of alanine, glutamine, and glutamate and decreased levels of glycine and branched-chain amino acids (BCAA; valine, leucine, and isoleucine). The suggested pathogenic mechanisms include increased flux of HIS through HIS degradation pathway (increases in ammonia and glutamate), increased ammonia detoxification to glutamine and exchange of the BCAA with glutamine via L-transporter system in muscles (increase in glutamine and decrease in BCAA), and tetrahydrofolate depletion (decrease in glycine). Increased alanine concentration is explained by enhanced synthesis in extrahepatic tissues and impaired transamination in the liver. Increased ammonia and glutamine and decreased BCAA levels in HIS-treated subjects indicate that HIS supplementation is inappropriate in patients with liver injury. The studies investigating the possibilities to elevate carnosine (β-alanyl-L-histidine) content in muscles show positive effects of β-alanine and inconsistent effects of HIS supplementation. Several studies demonstrate HIS depletion due to enhanced availability of methionine, glutamine, or β-alanine.

Key words: histidine supplementation; HTK solution; carnosine, beta-alanine, ammonia, glutamine, branched-chain amino acids; Bretschneider’s solution
Introduction

L-Histidine (HIS) and HIS-containing dipeptides (HCD), particularly carnosine, have been investigated for possible use in prevention and therapy of several disorders, such as Parkinson and Alzheimer diseases, metabolic syndrome, dermatitis, ulcers, and inflammatory bowel disease (Feng et al. 2013; Hisatsune et al. 2016, Baraniuk et al. 2013; Tan et al. 2017). Large doses of HIS supplements are used by people who believe that daily HIS consumption ameliorates feeling of fatigue, improves cognitive functions, and enhances muscle performance (Sasahara et al. 2015; Suzuki et al. 2006; Hill et al. 2007; Cornelli 2010). Large amounts of HIS are administered in cardiac surgery as a HIS-Tryptophan-Ketoglutarate (HTK) solution (Custodiol® HTK or Bretschneider’s solution) for induction of cardiac arrest and myocardial protection (Edelman et al. 2013). A volume of ~1.6 L of cardioplegic solution containing 198 mM HIS is infused causing an increase in plasma HIS concentration from ~70 µM to ~20,000 µM immediately after induction of cardioplegia (Teloh et al. 2016).

Despite frequent use of HIS and HCD in several indications, there is not enough information about HIS metabolism in context with metabolism of other amino acids. Only limited data exist in regard to the consequences of high HIS levels on concentrations of ammonia and other amino acids. HIS contains 3 atoms of nitrogen, which should appear as ammonia when HIS is catabolized (Fig. 1) and exert adverse effects on the function of several tissues, particularly of the liver and the kidneys. Little is also known as to how enhanced HIS intake affects the availability of carnosine, an efficient intracellular pH buffer in muscles (Abe 2000). An understanding of the effects of high HIS concentrations can also be applied in the exploration of metabolic changes associated with diseases. In the atherosclerosis risk in communities (ARIC) follow-up study, high serum HIS was negatively related to the risk of coronary heart disease among African- and European- Americans (Yu et al. 2015).

The main objective of the review is to explore the studies reporting the consequences of high HIS concentrations on the level and metabolism of other amino acids and to give some answers regarding the possible side effects of HIS administration. The second aim is to show the influences of other amino acids on HIS metabolism.
**Fig. 1** Pathways of HIS catabolism. The main pathway of HIS catabolism begins with deamination catalyzed by histidase to urocanate and leads through 4-imidazolone-5-propionate and FIGLU to GLU. Alternative pathways of HIS catabolism include transamination to imidazolepyruvate and decarboxylation to histamine.

1, histidase; 2, urocanase; 3, imidazolone propionate hydrolase; 4, glutamate formimino transferase; 5, glutamate dehydrogenase; 6, alanine aminotransferase; 7, glutaminase; 8, glutamine synthetase; 9, histidine aminotransferase; 10, histidine decarboxylase.

ALA, alanine; Asp, aspartic acid; FIGLU, formiminoglutamate; GLN, glutamine; GLU, glutamic acid; GLY, glycine; PYR, pyruvate; SAHC, S-adenosylhomocysteine; SAME, S-adenosylmethionine; SER, serine; THF, tetrahydrofolate; TCA cycle, tricarboxylic acid cycle; α-AA, α-amino acid; α-KA, α-keto acid; α-KG, α-ketoglutarate

**Effects of HIS administration on other amino acids**

*Studies reporting effects of high HIS concentrations on other amino acids*
The data from human and animal studies indicate that the most common findings in HIS-loaded (Table 1) and HIS-supplemented subjects (Table 2) are increased levels of alanine (ALA), glutamate (GLU), and glutamine (GLN) and decreased levels of glycine (GLY) and branched-chain amino acids (BCAA; valine, leucine, and isoleucine). In the following sections of the article, an attempt is made to clarify the pathogenesis of these alterations.

Pathogenesis of increased GLU and decreased GLY levels – role of the liver

In the liver, HIS administration increases the flux of HIS through HIS degradation pathway leading to GLU formation. Enhanced GLU production could also be due to hepatic glutaminase activated by increased ammonia level (Verhoeven et al. 1983). The formed GLU can be utilized by different pathways (Fig. 1). In the periportal zone of the liver lobule it may be converted to α-KG and ammonia by glutamate dehydrogenase. In perivenous zone of the lobule, which contains GLN synthetase and acts as a scavenger for the ammonia that escaped urea synthesis in periportal zone, GLU can be used for GLN synthesis. The studies examining the effects of dietary GLU demonstrated that significant amounts of GLU might be released by the liver to the blood (Cynober 2018). Hence, it may be suggested that in HIS-treated subjects, the liver enhances the release of GLU that escaped GLU dehydrogenase and GLN synthetase reactions, resulting in increased GLU concentrations in blood plasma. Most of the GLU released from the liver is removed by muscles, which use it for the synthesis of ALA and GLN (Cynober 2018; Klin et al. 2010). Increased GLN synthesis by perivenous hepatocytes probably plays a role in increased GLN concentrations in the blood; however, the skeletal muscle is more important source of GLN (discussed below).

It has been suggested that increased HIS degradation depletes tetrahydrofolate (THF) required for conversion of formiminoglutarate (FIGLU) to GLU and thus influences folate-dependent metabolic pathways of several amino acids, particularly GLY, methionine (MET), and serine (Arakawa et al. 1972). Meléndez-Hevia et al. (2009) proved that THF-dependent synthesis of GLY from serine accounts for more than 85 % of the total. Hence, the decrease in GLY concentrations reported in several studies examining the effects of HIS administration can be explained by THF depletion.
Pathogenesis of increased GLN and decreased BCAA levels in the blood - role of ammonia and muscles

An increased ammonia concentration in the blood in HIS-loaded and HIS-supplemented subjects (Holeček and Vodeničarovová 2019 and 2020) should originate from incomplete detoxification of ammonia produced from HIS catabolism in the liver to urea and increased HIS deamination to urocanate in the skin. Under these conditions, in skeletal muscle, alternative pathway of ammonia detoxification to GLN is activated (Fig. 2, left side). A supply of GLU, the second substrate for GLN synthetase reaction, is secured by the increased influx of GLU originating from HIS catabolism in the liver.

Most of the GLN synthesized in muscles is released to the blood by the exchange with the BCAA via L-transport system (Meier et al. 2002), resulting in increased GLN and decreased BCAA levels in the blood. GLN released from muscles can be effectively utilized by several tissues and exert favourable effects on gut integrity, the immune system, and protein balance (Newsholme and Hardy 1997). Hence, it may be suggested that some positive effects of HIS administration are mediated by GLN and that HIS supplementation is an alternative way to achieve GLN supplementation. The increased GLN concentrations in HIS-treated subjects may also be partially due to increased release by the liver of GLN synthesized by perivenous hepatocytes.

It should be emphasized that alterations in muscles associated with increased ammonia detoxification to GLN after HIS administration are substantially different from those induced by hyperammonaemia in liver cirrhosis and urea cycle disorders (Figure 2, right side). In the later conditions, ammonia detoxification to GLN causes intracellular depletion of GLU, drains α-KG from tricarboxylic acid (TCA) cycle (cataplerosis) resulting in mitochondrial dysfunction, and increases catabolism of the BCAA, which act as a donor of nitrogen to α-KG to form GLU (Wagenmakers 1990; Davuluri et al. 2016; Holeček and Vodeničarovová 2018). Furthermore, because of the liver injury, ammonia originating from GLN catabolism is not effectively detoxified to urea; thus, ammonia may exert its toxic effects on the brain and could be detoxified to GLN in the muscles. As a result, a vicious cycle is activated in which an enhanced ammonia concentration activates synthesis of GLN leading to its subsequent catabolism and an increased ammonia level in the blood (Holeček 2014).
**FIG. 2.** Consequences of ammonia detoxification to GLN in muscles after HIS administration (left side) and in liver injury (right side).

ALA, alanine; BCAA, branched-chain amino acids; BCKA, branched-chain keto acids; GLU, glutamic acid; GLN, glutamine; HIS, histidine; PYR, pyruvate; TCA cycle, tricarboxylic acid cycle; α-KG, α-ketoglutarate

*Pathogenesis of increased ALA levels*

The pathogenesis of markedly increased ALA levels in blood, muscles, and the liver in HIS-treated subjects is complex. In addition to an increased synthesis of ALA from GLU in muscles (Fig. 2, left side), a significant role in ALA synthesis is played by histidine aminotransferase, the first enzyme of alternative pathway of HIS catabolism (Fig. 1). This enzyme exists in two isoforms (Noguchi et al. 1976). Isoenzyme 1 is expressed only in the liver and is active towards pyruvate and α-ketoglutarate. Isoenzyme 2 is expressed in the liver, kidneys, heart, and skeletal muscle and is active only towards pyruvate resulting in ALA formation. Moreover, since the alanine aminotransferase reaction is reversible and near equilibrium, a rise in GLU concentration in the liver would inhibit ALA conversion to pyruvate (see Fig. 1). A role in increased ALA concentration may have also ALA synthesis from GLN by enterocytes (Windmueller and Spaeth 1975). Whether or not increased ALA concentrations in HIS-treated subjects should be of concern is not clear.
Effects of altered amino acid transport across cell membranes

Because HIS shares its cellular transporters with other amino acids, an effect of competition may alter the transport of other amino acids and their distribution among tissues. The competition between HIS and other amino acids for transporters has undoubtedly a significant influence during the early phase after loading with a large dose of HIS, as occurs after infusion of HTK solution in cardiac surgery. Increased concentrations of most of the amino acids in blood plasma are observed, along with decreased amino acid concentrations in tissues and remarkably increased urinary loss of most amino acids 1 or 2 hours after the HIS load (Holton 1968; Hamblin and Holton 1972; Holeček and Vodeníčarovová 2019).

The competition between HIS and other amino acids for transport seems to play an important role in the brain. Since HIS is transported into the brain principally on the large neutral amino acid (LNAA) carrier (Oldendorf and Szabo 1976; Oldendorf et al. 1988) that also transports aromatic amino acids (AAA; tyrosine, phenylalanine, and tryptophan), decreased transport of AAA may alter the synthesis of several neurotransmitters, particularly serotonin, dopamine, and norepinephrine.

A precipitous rise in serum HIS would increase HIS levels in the brain and its metabolism to histamine. The findings of histamine elevations in brain in HIS-injected and HIS-consuming rats (Sheiner et al. 1985; Lozeva et al. 2003) led to suggestion that daily HIS consumption ameliorates feeling of fatigue and improves attentiveness (Sasahara et al. 2015). There are reports of positive effects of dried bonito broth, called dashi, that contains high amounts of HIS, on mood in healthy subjects and subjects with fatigue symptoms (Kuroda et al. 2007; Nozawa et al. 2008). However, studies examining the role of a high HIS concentration on maintenance of neurotransmitter pools in the brain are inconclusive, and more rigorous studies are needed to clarify the effect of HIS supplementation on brain functions.

Effects of HIS administration on content of HCD
HCD found in vertebrates include anserine (beta-alanyl-N1-methylhistidine), carnosine (beta-alanyl-L-histidine), homocarnosine (gamma-aminobutyryl-L-histidine), balenine (ophidine, beta-alanyl-N3-methylhistidine), acetyl carnosine (N-acetyl-β-alanyl-L-histidine), and carcinine (beta-alanylhistamine). The only HCD synthetized in humans are carnosine and homocarnosine. Carnosine is mainly found in skeletal muscle, while homocarnosine is exclusively present in the brain.

Homocarnosine acts as a source gamma-aminobutyric acid (GABA) in specific tracts of CNS (Jackson et al. 1994). Carnosine is a more efficient intracellular pH buffer and antioxidant than is free HIS (Dahl et al. 1988; Hartman et al. 1990). In accordance with its anaerobic energy delivery in fast-twitch muscles, carnosine and anserine contents are higher in fast-twitch (white) muscles as compared with slow-twitch (red) muscles (Abe 2000; Hill et al. 2007; Holeček and Vodeničarovová 2019). It is assumed that an increase in muscle carnosine content may have some benefits for athletes and elderly, as well as in treating various disorders. Unfortunately, the reports of the effects of HIS supplementation on the level of HCD are not entirely conclusive (Table 3).

Effects of other amino acids on HIS metabolism

Knowledge of the mechanism how certain amino acid affects the metabolism of other amino acids can contribute to better understanding of the complex interconnections of individual amino acids metabolism. Several articles have demonstrated significant effects of GLN, MET, and β-alanine on HIS levels in blood and tissues.

Effects of GLN

Consumption of a GLN-enriched diet by rats for 3 months increased HIS and GLN concentrations in the blood plasma and muscles, whereas the level of other amino acids decreased or were unchanged (Holeček 2011). The effect was not observed in the gut, liver, and kidneys. In another studies, performed under in vitro conditions, the HIS concentration decreased in muscles incubated in GLN-enriched medium (Holeček et al. 2015) and increased in muscles incubated in GLN-deficient medium (Holeček and Šišpera 2014).
These findings might be explained by influence of GLN on the amino acid transport system N, which has a narrow substrate specificity of GLN, HIS, and asparagine (Leonardi et al. 1988). Competition between GLN and HIS for the transporter may explain the enhanced blood HIS concentrations in subjects consuming a GLN-enriched diet, the decreased HIS concentration in muscles incubated in medium with a high GLN concentration, and the increased HIS concentration in muscles incubated in GLN-deficient medium. A similar system (designated system N\textsuperscript{m}) is involved in the release of GLN from muscle (Rennie et al. 1986) and might be responsible for increases in HIS concentration in the muscles of animals chronically fed a GLN-enriched diet.

*Effects of MET*

Fell and Stele (1983) conducted several experiments to examine the effects of MET on HIS metabolism in rats. An experiment in which rats were fed a MET-enriched diet for at least 10 days revealed a 49 % reduction of plasma HIS and an 80 % reduction in urinary excretion of FIGLU. When a 100 mg HIS load was given on day 5, urinary FIGLU excretion was 83% lower in MET-supplemented animals relative to controls. The experiment using labeled HIS showed that MET-supplemented animals oxidized 21 % more HIS than controls, although histidase and urocanase activities were unaffected. A study by other authors has shown that addition of MET, S-adenosylmethionine, homocysteine, or S-adenosylhomocysteine to isolated rat hepatocytes increased HIS oxidation two- to fourfold (Billings et al. 1981). All these studies showed that MET supplementation may activate HIS catabolism by increasing the availability of THF generated by the MET cycle during conversion of homocysteine to MET (Fig. 1).

*Effects of β-alanine*

β-Alanine is considered to be the rate-limiting precursor of carnosine synthesis in humans (Blancquaer et al. 2017) and several studies have demonstrated that β-alanine supplementation increases intracellular carnosine concentration and subsequently improves high-intensity exercise
Therefore, chronic oral β-alanine supplementation is becoming a popular ergogenic strategy. However, the consequences of β-alanine supplementation on HIS metabolism are not completely clear. Blancquaert et al. (2017) showed in humans a substantial HIS decline (~30%) in muscles and plasma after 23 days of β-alanine supplementation (6 g/day) and hypothesized that increased intake of β-alanine gradually depletes HIS via a failure of dietary intake to match the increasing use of HIS for carnosine synthesis. In another, methodologically similar study, β-alanine supplementation did not reduce HIS in muscles (Varanoske et al. 2017). The authors speculated that the discrepancy between their study and that of Blancquaert is due to the differences in dietary HIS intake between American and Belgian population. Obviously, further studies are needed to determine whether β-alanine supplementation requires a concomitant increase in HIS intake.

CONCLUSIONS

1. The data from human and animal studies show marked alterations in some amino acid concentrations in HIS-loaded and HIS-supplemented subjects. The most common are increased ALA, GLU, and GLN and decreased GLY and BCAA levels in blood plasma. These findings seem to be due to increased HIS flux through HIS degradation pathway (increases in ammonia and GLU), increased GLN synthesis in muscles and BCAA/GLN exchange through muscle cell membranes (increase in GLN and decrease in BCAA), and THF depletion (decrease in GLY). High levels of ALA are explained by increased activity of HIS transferase in several tissues and impaired ALA transamination in the liver due to increased GLU availability.

2. Increased ammonia and GLN and decreased BCAA levels in HIS-treated subjects indicate that HIS supplementation is inappropriate in patients with liver injury (GLN can be catabolized to ammonia; decreased BCAA levels have adverse effect on protein balance and mental function in patients with hepatic encephalopathy).

3. The studies investigating the possibilities to elevate carnosine content in muscles show positive effect of β-alanine and inconsistent effects of HIS supplementation.

4. Several studies demonstrated HIS depletion as a consequence of enhanced availability of MET, GLN, or β-alanine.
Conflict of Interest
The authors declare that there are no conflicts of interest.

Acknowledgements
Supported by the programme PROGRES Q40/02.

References


41. RENNIE MJ, HUNDAL HS, BABIJ P, MACLENNAN P, TAYLOR PM, WATT PW, JEPSON MM, MILLWARD DJ: Characteristics of a glutamine carrier in skeletal muscle
have important consequences for nitrogen loss in injury, infection, and chronic disease. Lancet 2(8514): 1008-1012, 1986.


Table 1. Effects of acute load of a large dose of HIS on amino acid, ammonia, and ATP concentrations

<table>
<thead>
<tr>
<th>Study design</th>
<th>Main findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humans, antegrade cardioplegia (HTK solution, 1.6 L)</td>
<td>Plasma: ↑ HIS, GLU, ALA, GLN, Asp, and Asn</td>
<td>Teloh et al. 2016</td>
</tr>
<tr>
<td></td>
<td>Urine: ↑ HIS, GLU, and GLN (samples collected during surgery)</td>
<td></td>
</tr>
<tr>
<td>Normal human subjects, HIS load (15 g orally)</td>
<td>Plasma at 1 or 2 hours:</td>
<td>Holton 1968</td>
</tr>
<tr>
<td></td>
<td>↑ HIS, GLY, ALA, Tau, Thr, Ser, Lys, and Arg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↓ BCAA, Tyr, Phe, and Orn</td>
<td></td>
</tr>
<tr>
<td>Normal human subjects, HIS load (75 mg/kg body weight, intravenously)</td>
<td>Plasma at 1 hour:</td>
<td>Hamblin and Holton 1972</td>
</tr>
<tr>
<td></td>
<td>↑ in most amino acids, especially ALA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plasma at 3 hours:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>↓ in nearly all amino acids</td>
<td></td>
</tr>
<tr>
<td>Rats, HIS load (800 µmol/rat, intravenously)</td>
<td>At 2 hours:</td>
<td>Holeček and Vodeničarovová 2019</td>
</tr>
<tr>
<td></td>
<td>Plasma: ↑ HIS, ALA, GLU, GLN, Asp, urea, ammonia; ↓GLY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urine: ↑ urea, ammonia, and all amino acids</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liver: ↑ HIS and GLU; ↓ GLY, GLN, Tau, and ATP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Muscles: ↑ HIS; ↓ GLY, Ser, and ATP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>At 24 hours:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plasma: ↓ BCAA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Muscles: ↑ ammonia; ↓ BCAA and ATP</td>
<td></td>
</tr>
<tr>
<td>Rats, HIS load (0.5 or 1.0 g/kg body weight, intraperitoneally)</td>
<td>At 1 hour:</td>
<td>Tyfield and Holton 1975</td>
</tr>
<tr>
<td></td>
<td>Plasma: ↑ HIS, ALA, and GLN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brain: ↑ HIS, ALA, and GLN; ↓ BCAA, MET, Tyr, and Phe</td>
<td></td>
</tr>
</tbody>
</table>

Amino acid abbreviations in capital letters indicate the amino acids specifically discussed in the article.
Table 2. Effects of chronic HIS consumption on amino acid concentrations

<table>
<thead>
<tr>
<th>Study design</th>
<th>Main findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rats, HIS-enriched diet (7% or 14% HIS) for 8 days</td>
<td>Plasma: ↑ HIS; ↓ BCAA, GLY, and Thr Brain: ↑ HIS and GLN; ↓ Val and Thr</td>
<td>Tyfield and Holton 1975</td>
</tr>
<tr>
<td>Cats, HIS-enriched diets (0.6, 1.0, and 1.4%) for 2 weeks</td>
<td>Plasma: ↑ HIS and GLN; ↓ GLY</td>
<td>Martin et al. 2012</td>
</tr>
<tr>
<td>Rats, HIS in drinking water (0.5 or 2.0 g/L) for 4 weeks</td>
<td>Plasma: ↑ HIS, ALA, GLU, Pro, Asp, and ammonia Liver: ↑ HIS and ALA ↓ GLY, MET, and Asp Muscles: ↑ HIS, ALA, GLN</td>
<td>Holeček and Vodeničarovová 5020</td>
</tr>
<tr>
<td>Obese women, HIS (4 g/day) for 12 weeks</td>
<td>Plasma: ↑ HIS, ALA, GLN, GLY, Lys, Asp ↓ Leu, Ile, Phe, Trp, and Tau</td>
<td>Du et al. 2017</td>
</tr>
</tbody>
</table>

Amino acid abbreviations in capital letters indicate the amino acids specifically discussed in the article.
**Table 3.** Effects of HIS administration on content of HCD

<table>
<thead>
<tr>
<th>Study design</th>
<th>Main findings</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rats, HIS-enriched diet (7 % or 14 % HIS) for 8 days.</td>
<td>↑ homocarnosine (brain)</td>
<td>Tyfield and Holton 1975</td>
</tr>
<tr>
<td>Rats, HIS-depleted or HIS-enriched (5 %) diet for 2 weeks.</td>
<td>↓ anserine and carnosine in gastrocnemius muscle in HIS-depleted animals ↑ carnosine and anserine in gastrocnemius muscle in rats fed a HIS-enriched diet</td>
<td>Tamaki et al. 1977</td>
</tr>
<tr>
<td>Humans, HIS (3.5 g/day), β-alanine (6.0 g/day) or combination, orally for 23 days.</td>
<td>No effect in HIS-supplemented subjects. ↑ carnosine in m. vastus lateralis after β-alanine or combined therapy.</td>
<td>Blancquaert et al. 2017</td>
</tr>
<tr>
<td>Rats, HIS in drinking water (0.5 or 2.0 g/L) for 4 weeks</td>
<td>↓ anserine in soleus muscle but not in extensor digitorum longus and tibialis muscles No effect on carnosine</td>
<td>Holeček and Vodeničarovová 2020</td>
</tr>
<tr>
<td>Rats, HIS load (800 µmol HIS/rat intravenously).</td>
<td>↑ carnosine in soleus but not in extensor digitorum longus muscles at 24 hours</td>
<td>Holeček and Vodeničarovová 2019</td>
</tr>
</tbody>
</table>